[Form 3] bioAffinity Technologies, Inc. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Roberto Rios, a director of bioAffinity Technologies, Inc. (BIAF), filed an initial Form 3 disclosing beneficial ownership of 833 shares of the company's common stock. The event requiring the statement occurred on 08/12/2025 and the Form 3 bears a signature date of 09/25/2025. The filing indicates direct ownership and does not disclose any derivative securities or indirect holdings.

Insights

Corporate Governance Expert

TL;DR: Initial director disclosure of a small direct stake; routine governance compliance.

This Form 3 reports a modest direct holding of 833 common shares by Director Roberto Rios, reflecting initial compliance with Section 16 reporting requirements. The filing contains no derivative positions and no indirect ownership descriptions, suggesting no complex compensation arrangements or related-party holdings disclosed here. For governance, the filing is procedural and does not signal material change to control or board incentives.

Securities Analyst

TL;DR: Non-material ownership disclosure; no market-moving details provided.

The disclosure shows direct ownership only and lacks any exercise prices, warrants, or options. The amount, 833 shares, is small relative to typical market-cap stakes and is unlikely to affect valuation or voting outcomes. This is a standard initial insider report that confirms reporting timelines were met; it provides limited information for financial analysis.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Rios Roberto

(Last) (First) (Middle)

C/O BIOAFFINITY TECHNOLOGIES, INC.,

3300 NACOGDOCHES ROAD, SUITE 216

(Street)

SAN ANTONIO, TX 78217

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/12/2025

3. Issuer Name and Ticker or Trading Symbol
bioAffinity Technologies, Inc. [ BIAF ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	833	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Roberto Rios	09/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Roberto Rios disclose on the Form 3 for BIAF?

The Form 3 discloses that Roberto Rios directly owns 833 shares of bioAffinity Technologies, Inc. common stock.

When did the event requiring the Form 3 occur for BIAF?

The event date reported on the Form 3 is 08/12/2025.

Does the Form 3 for BIAF report any derivative securities or indirect ownership?

No. The Form 3 shows no derivative securities and lists the shares as held directly.

What is the filing/signature date on the Form 3 submitted by Roberto Rios?

The Form 3 is signed by Roberto Rios on 09/25/2025.

What is Roberto Rios's role at bioAffinity Technologies (BIAF)?

The Form 3 identifies Roberto Rios as a Director of bioAffinity Technologies, Inc.